LEADER 01111nam a2200265 i 4500
001 991002271079707536
005 20020508193402.0
008 940804s1967    us            ||| | eng  
035   $ab1098446x-39ule_inst
035   $aPARLA158502$9ExL
040   $aDip.to Filol. Class. e Med.$bita
082 0 $a910
100 1 $aCosmas : Indicopleustes$0297422
245 10$a[Christianiké topographia] :$bthe christian topography of Cosmas, an Egyptian monk /$ctranslated from the greek, and edited, with notes and introduction by J. W. McCrindle
260   $aNew York :$bFranklin,$c[1967]
300   $axii, xxvii, 398 p.: ill. ;$c23 cm.
490 0 $aWorks issued by the Hakluyt Society, 1st ser. ;$v98
500   $aReprint of the 1897 ed.
700 1 $aMcCrindle, John Watson
907   $a.b1098446x$b23-02-17$c28-06-02
912   $a991002271079707536
945   $aLE007 880.1 Cosmas Ind. MCC 01.01$g1$i2007000004937$lle007$o-$pE0.00$q-$rl$s-  $t0$u0$v0$w0$x0$y.i1109770x$z28-06-02
996   $aChristianiké topographia$91395456
997   $aUNISALENTO
998   $ale007$b01-01-94$cm$da  $e-$feng$gus $h0$i1

LEADER 02519nam  2200553   450 
001 9910789364703321
005 20200520144314.0
010   $a0-309-26940-7
035   $a(CKB)3710000000103236
035   $a(EBL)3564286
035   $a(SSID)ssj0001119888
035   $a(PQKBManifestationID)12436835
035   $a(PQKBTitleCode)TC0001119888
035   $a(PQKBWorkID)11150013
035   $a(PQKB)11081283
035   $a(MiAaPQ)EBC3564286
035   $a(Au-PeEL)EBL3564286
035   $a(CaPaEBR)ebr10863743
035   $a(OCoLC)839275199
035   $a(EXLCZ)993710000000103236
100   $a20140127h20132013  uy|            0
101 0 $aeng
135   $aurcnu||||||||
181   $ctxt
182   $cc
183   $acr
200 10$aCountering the problem of falsified and substandard drugs /$fCommittee on Understanding the Global Public Health Implications of Substandard, Falsified, and Counterfeit Medical Products, Board on Global Health ; Gillian J. Buckley and Lawrence O. Gostin, editors ; Institute of Medicine of the National Academies
210  1$aWashington, District of Columbia :$cNational Academies Press,$d[2013]
210  4$d©2013
215   $a1 online resource (375 p.)
300   $aDescription based upon print version of record.
311   $a0-309-26939-3 
320   $aIncludes bibliographical references.
327   $a""Front Matter""; ""Reviewers""; ""Acknowledgments""; ""Acronyms and Abbreviations""; ""Contents""; ""Boxes, Figures, and Tables""; ""Summary""; ""1 Introduction""; ""2 The Effects of Falsified and Substandard Drugs""; ""3 The Magnitude of the Problem""; ""4 Causes of Falsified and Substandard Drugs""; ""5 Weaknesses in the Drug Distribution Chain""; ""6 Detection Technology""; ""7 An International Code of Practice for Falsified and Substandard Medicines""; ""Appendix A: Glossary""; ""Appendix B: Committee Biographies""; ""Appendix C: Meeting Agendas""
606   $aPharmaceutical industry$xQuality control
606   $aFraud$xPrevention
615  0$aPharmaceutical industry$xQuality control.
615  0$aFraud$xPrevention.
676   $a364.1668
702   $aBuckley$b Gillian J.
702   $aGostin$b Lawrence O$g(Lawrence Ogalthorpe),
712 02$aInstitute of Medicine.$bBoard on Global Health,
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910789364703321
996   $aCountering the problem of falsified and substandard drugs$93788909
997   $aUNINA